Swedish Orphan Biovitrum AB (Sobi)
↗Stockholm, Sweden
Sobi is an international biopharmaceutical company dedicated to transforming the lives of people living with rare and debilitating diseases. The company provides sustainable access to innovative therapies, with a primary focus on haematology, immunology, and specialty care. Sobi operates across the entire value chain, from research and development to manufacturing and global commercialization.
Headquartered in Stockholm, Sweden, Sobi maintains a global footprint with a presence in approximately 30 countries and delivers medicines to patients in over 60 countries. The company is known for its integrated approach, combining in-house capabilities with strategic partnerships to advance its pipeline of biologics and specialty medicines.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:SEK 28B (2025)
Founded:2010
Ownership:public
Status:operating
FUNDING
Investors:Investor AB
STOCK
Exchange:NASDAQ Stockholm
Ticker:SOBI
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Biologics, Recombinant proteins, Monoclonal antibodies, Small molecule
Active Trials:207
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Selecta Biosciences (Cartesian Therapeutics) - NASP/SEL-212 development
COMPETITION
Position:Leader
Competitors:Alexion Pharmaceuticals, BioMarin Pharmaceutical, Sanofi
LEADERSHIP
Key Executives:
Guido Oelkers - CEO
Lydia Abad-Franch - Head of R&D and Medical Affairs, CMO
LINKS
Website:sobi.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Swedish Orphan Biovitrum AB (Sobi) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Swedish Orphan Biovitrum AB (Sobi). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.